[printfriendly]
December 2013—Transgenomic has entered into a collaborative agreement with PerkinElmer to market and distribute Transgenomic’s oncology diagnostic test portfolio of products in territories outside the United States.
Under terms of the agreement, effective Jan. 1, 2014, PerkinElmer will have the nonexclusive right to sell, market, distribute, and perform field service activities outside the United States for Transgenomic’s line of molecular diagnostic oncology products, including CRC RAScan and ACE kits, for use on the PerkinElmer LabChip MultiDx platform.
The CRC RAScan provides a single-kit solution for detecting KRAS and NRAS genetic mutations that are highly relevant when considering administration of select EGFR inhibitor therapies associated with metastatic colorectal cancer.
The initial launch will be in Europe. Financial terms of the agreement were not disclosed.
Transgenomic, 402-452-5416